Bin Yan, Haijun Guo, Tianxi Hu, Yu Zhang, Zhixin Zheng, Weipeng Du, Yuhan Gu
{"title":"基于机器学习方法的深静脉血栓诊断模型的开发与验证。","authors":"Bin Yan, Haijun Guo, Tianxi Hu, Yu Zhang, Zhixin Zheng, Weipeng Du, Yuhan Gu","doi":"10.1007/s00277-025-06628-z","DOIUrl":null,"url":null,"abstract":"<p><p>The D-Dimer testing has limited diagnostic value for patients with a deep venous thrombosis (DVT) probability based on clinical prediction rules. There are still patients with normal D-Dimer levels (< 500 ng/mL) diagnosed with DVT. Some new predictive marker may improve the predictive power of D-Dimer, especially in DVT patients with normal levels of D-Dimer. All subjects were from Nanyang Central Hospital. The demographic data and laboratory test data were collected. Multiple models were used to evaluate and calculate the importance rank. Multivariate logistics was used to establish a DVT diagnostic model. Compared to D-Dimer and other markers, this combined model has better performance. The von Willebrand factor Gain-of-function mutant GPIb binding assays (VWF: GPIbM) can improve the diagnostic capability of D-Dimer, which has higher diagnostic value and clinical benefits. In addition, the model still has good diagnostic capability in DVT patients with normal D-Dimer levels. The combined model has better diagnostic performance than D-Dimer, and it is valuable for some patients whose clinical prediction rules cannot be evaluated due to difficulties in obtaining medical history information. VWF: GPIbM can be used to assist in the diagnosis of DVT in the future.</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Development and validation of deep vein thrombosis diagnostic model based on machine learning methods.\",\"authors\":\"Bin Yan, Haijun Guo, Tianxi Hu, Yu Zhang, Zhixin Zheng, Weipeng Du, Yuhan Gu\",\"doi\":\"10.1007/s00277-025-06628-z\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The D-Dimer testing has limited diagnostic value for patients with a deep venous thrombosis (DVT) probability based on clinical prediction rules. There are still patients with normal D-Dimer levels (< 500 ng/mL) diagnosed with DVT. Some new predictive marker may improve the predictive power of D-Dimer, especially in DVT patients with normal levels of D-Dimer. All subjects were from Nanyang Central Hospital. The demographic data and laboratory test data were collected. Multiple models were used to evaluate and calculate the importance rank. Multivariate logistics was used to establish a DVT diagnostic model. Compared to D-Dimer and other markers, this combined model has better performance. The von Willebrand factor Gain-of-function mutant GPIb binding assays (VWF: GPIbM) can improve the diagnostic capability of D-Dimer, which has higher diagnostic value and clinical benefits. In addition, the model still has good diagnostic capability in DVT patients with normal D-Dimer levels. The combined model has better diagnostic performance than D-Dimer, and it is valuable for some patients whose clinical prediction rules cannot be evaluated due to difficulties in obtaining medical history information. VWF: GPIbM can be used to assist in the diagnosis of DVT in the future.</p>\",\"PeriodicalId\":8068,\"journal\":{\"name\":\"Annals of Hematology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2025-09-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Hematology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00277-025-06628-z\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00277-025-06628-z","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
d -二聚体检测对基于临床预测规则的深静脉血栓形成(DVT)概率患者的诊断价值有限。仍有患者d -二聚体水平正常(
Development and validation of deep vein thrombosis diagnostic model based on machine learning methods.
The D-Dimer testing has limited diagnostic value for patients with a deep venous thrombosis (DVT) probability based on clinical prediction rules. There are still patients with normal D-Dimer levels (< 500 ng/mL) diagnosed with DVT. Some new predictive marker may improve the predictive power of D-Dimer, especially in DVT patients with normal levels of D-Dimer. All subjects were from Nanyang Central Hospital. The demographic data and laboratory test data were collected. Multiple models were used to evaluate and calculate the importance rank. Multivariate logistics was used to establish a DVT diagnostic model. Compared to D-Dimer and other markers, this combined model has better performance. The von Willebrand factor Gain-of-function mutant GPIb binding assays (VWF: GPIbM) can improve the diagnostic capability of D-Dimer, which has higher diagnostic value and clinical benefits. In addition, the model still has good diagnostic capability in DVT patients with normal D-Dimer levels. The combined model has better diagnostic performance than D-Dimer, and it is valuable for some patients whose clinical prediction rules cannot be evaluated due to difficulties in obtaining medical history information. VWF: GPIbM can be used to assist in the diagnosis of DVT in the future.
期刊介绍:
Annals of Hematology covers the whole spectrum of clinical and experimental hematology, hemostaseology, blood transfusion, and related aspects of medical oncology, including diagnosis and treatment of leukemias, lymphatic neoplasias and solid tumors, and transplantation of hematopoietic stem cells. Coverage includes general aspects of oncology, molecular biology and immunology as pertinent to problems of human blood disease. The journal is associated with the German Society for Hematology and Medical Oncology, and the Austrian Society for Hematology and Oncology.